Research Interest Statement:
I am interested in exploring the molecular mechanisms T cells utilize to sense and adapt to environmental stress, focusing on the immune control of cancer. My work utilizes specialized proteomic approaches to established immune monitoring strategies and to inform the development of cellular therapies.
“EPIGENETIC REGULATION OF METABOLIC STRESS PATHWAYS IN MELANOMA INFILTRATING LYMPHOCYTES”
03/01/19 – 02/28/22
NIH/Nat. Cancer Institute – 1F31CA232464
“Epigenetic regulation of metabolic stress pathways in melanoma infiltrating lymphocytes- Resubmission”
03/01/19 – 02/28/22
Koss B, Shields BD, Taylor EM, [et al.]. Epigenetic Control of Cdkn2a.Arf Protects Tumor-Infiltrating Lymphocytes from Metabolic Exhaustion. Cancer research. 2020. PMID: 33004350.
Trentzsch M, Nyamugenda E, Miles TK, [et al., including Koss B]. Delivery of phosphatidylethanolamine blunts stress in hepatoma cells exposed to elevated palmitate by targeting the endoplasmic reticulum. Cell death discovery. 2020 6:8. PMID: 32123584. PMCID: PMC7028721.
Taylor EM, Koss B, Davis LE, Tackett AJ. Histone Modifications as Biomarkers for Immunotherapy. Methods in molecular biology (Clifton, N.J.). 2020 2055:213-228. PMID: 31502154.
Ren Z, Ahn JH, Liu H, [et al., including Koss B]. PHF19 promotes multiple myeloma tumorigenicity through PRC2 activation and broad H3K27me3 domain formation. Blood. 2019 134(14):1176-1189. PMID: 31383640. PMCID: PMC6776795.
Chiang TC, Koss B, Su L, [et al.]. Effect of Sulforaphane and 5-Aza-2'-Deoxycytidine on Melanoma Cell Growth. Medicines (Basel, Switzerland). 2019 6(3). PMID: 31252639. PMCID: PMC6789461.
Lee T, Christov PP, Shaw S, [et al., including Koss B]. Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors That Demonstrate in Vivo Activity in Mouse Xenograft Models of Human Cancer. Journal of medicinal chemistry. 2019 62(8):3971-3988. PMID: 30929420.
Shields BD, Koss B, Taylor EM, [et al.]. Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma. Cancer research. 2019 79(6):1113-1123. PMID: 30674537. PMCID: PMC6420873.
Shields BD, Mahmoud F, Taylor EM, [et al., including Koss B]. Indicators of responsiveness to immune checkpoint inhibitors. Scientific reports. 2017 7(1):807. PMID: 28400597. PMCID: PMC5429745.
Lee T, Bian Z, Zhao B, [et al., including Koss B]. Discovery and biological characterization of potent myeloid cell leukemia-1 inhibitors. FEBS letters. 2017 591(1):240-251. PMID: 27878989. PMCID: PMC5381274.
Koss B, Ryan J, Budhraja A, [et al.]. Defining specificity and on-target activity of BH3-mimetics using engineered B-ALL cell lines. Oncotarget. 2016 7(10):11500-11. PMID: 26862853. PMCID: PMC4905489.
Haverkamp JM, Smith AM, Weinlich R, [et al., including Koss B]. Myeloid-derived suppressor activity is mediated by monocytic lineages maintained by continuous inhibition of extrinsic and intrinsic death pathways. Immunity. 2014 41(6):947-59. PMID: 25500368. PMCID: PMC4272664.